| Identification | Back Directory | [Name]
Glycine, (2S)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) | [CAS]
439087-68-0 | [Synonyms]
Glycine, (2S)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl- (9CI) | [Molecular Formula]
C36H45N3O7S2 | [MOL File]
439087-68-0.mol | [Molecular Weight]
695.89 |
| Chemical Properties | Back Directory | [Boiling point ]
969.6±65.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
3.20±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
(S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors[1][2][3]. | [References]
[1] Wong BS, et al. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb; 22(2):277-84. DOI:10.1517/13543784.2013.753056
[2] Sugiyama Y, et al. Impact of elobixibat on liver tumors, microbiome, and bile acid levels in a mouse model of nonalcoholic steatohepatitis. Hepatol Int. 2023 Dec;17(6):1378-1392. DOI:10.1007/s12072-023-10581-2
[3] Yamauchi R, et al. Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice. Hepatol Int. 2021 Apr;15(2):392-404. DOI:10.1007/s12072-020-10107-0 |
|
|